Summary

Efepoetin alfa is a synthetic erythropoiesis-stimulating agent (ESA) that mimics erythropoietin (EPO) through a peptide scaffold. Unlike recombinant EPO proteins, efepoetin alfa uses a designed peptide that reproduces EPO's receptor-binding activity. It has completed Phase 3 trials for the treatment of anaemia in chronic kidney disease (CKD), demonstrating non-inferiority to methoxy polyethylene glycol-epoetin beta. The compound exemplifies structure-based peptide design applied to a clinically important target. For research and educational purposes only.

Mechanism

Efepoetin alfa is a peptide mimetic of erythropoietin (EPO). It binds and activates the erythropoietin receptor (EPOR), triggering JAK2/STAT5 signalling that stimulates erythroid progenitor cell proliferation, differentiation, and red blood cell production. The peptide scaffold reproduces the receptor-binding epitope of EPO without requiring the full 165-amino-acid glycoprotein structure.

Evidence base

Strong evidence — Phase 3 randomised, active-controlled trial (NCT05109593; PMID 40369895) demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in maintaining haemoglobin levels in Stage 3-4 CKD patients with anaemia. Safety profile consistent with the ESA class. Evidence for non-CKD indications remains investigational.

Key trial: NCT05109593; published 2025 (PMID: 40369895)

Protocols

Phase 3 dose (SC): Subcutaneous injection, dose by body weight and baseline haemoglobin, monthly dosing interval.

Titration: Haemoglobin monitored every 2-4 weeks; dose adjusted to maintain 10-12 g/dL.

Iron: Maintain TSAT ≥20% and ferritin ≥100 ng/mL.

Research use only — not medical advice.

Work out the draw →

UK Status: POM (Prescription-Only Medicine)

Efepoetin alfa is classified as a prescription-only medicine. It is not currently MHRA-licensed (regulatory submissions in progress). It is not a controlled substance under the Misuse of Drugs Act 1971. Research institutions may source non-clinical material for in vitro or animal research under appropriate licensing.

References

  1. Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. PubMed. 2025. PMID: 40369895.
  2. ClinicalTrials.gov. NCT05109593. A Study to Evaluate the Efficacy and Safety of Efepoetin Alfa in Participants With CKD and Anaemia.
  3. Jelkmann W. Erythropoietin: Structure, Control of Production, and Function. Physiol Rev. 1992;72(2):449-489.
  4. Elliott S, Pham E, Macdougall IC. Erythropoietins: A Common Mechanism of Action. Exp Hematol. 2008;36(1):24-34.